Start Your Search
MA03 - Clinomics and Genomics (ID 119)
- Event: WCLC 2019
- Type: Mini Oral Session
- Track: Advanced NSCLC
- Presentations: 1
- Now Available
- Moderators:Heather A Wakelee, Wilfried Ernst Erich Eberhardt
- Coordinates: 9/08/2019, 10:30 - 12:00, Colorado Springs (1994)
MA03.01 - The Impact of Early Steroids on Clinical Outcomes in Patients with Advanced NSCLC Treated with Immune Checkpoint Inhibitors- A Cancerlinq Cohort (Now Available) (ID 2807)
10:30 - 12:00 | Author(s): Xuefei Jia
Immune checkpoint inhibitors (ICIs) have changed the treatment paradigm for patients with NSCLC, however only a fraction of patients have objective responses to these agents. Identifying clinical factors that influence efficacy of ICIs is crucial for optimal patient selection for treatment. Since ICIs produce anti-tumor responses by reinvigorating cytotoxic effector T cells, one can surmise that patients who receive steroids within a short interval of initiating ICIs will have less robust anti-tumor responses. Clinical trials usually exclude patients receiving steroids for this reason. In clinical practice, patients with NSCLC often receive corticosteroids for various indications such as brain metastases, appetite stimulation, autoimmune disorders, or COPD. By analyzing data obtained from a large real world cohort of patients with NSCLC, we aim to study the impact of early steroids (within 30 days) on clinical outcomes in patients with advanced NSCLC treated with ICIs.Method
Using the Cancerlinq Discovery Database which consists of data aggregated from the electronic medical records of oncology practices, 11,143 patients with advanced NSCLC treated with ICIs were identified. Of these, 1581 patients were prescribed or administered ≥ 10 mg of prednisone or equivalent corticosteroid dose within the first 30 days of initiating ICIs. To account for prognostic heterogeneity within the population, we created matched cohorts of patients that exhibited similar prognostic clinical characteristics such as age (using 65 years as a cutoff) and gender. Association between time on treatment with ICIs and early steroid use was evaluated using the Student’s t-test. Overall survival (OS) was estimated using the Kaplan-Meier method and analyzed using the Cox proportional-hazards model.Result
The cohort consisted of a predominantly white population (53.4%), with a median age of 76 years and a slight male predominance (54.9%). The median time on ICI treatment was 3.8 months. Patients who received steroids within the first 30 days had a shorter time on treatment- median of 3.36 months vs 3.86 months for those without steroid use (p= 0.023). Early steroid use was also associated with significantly worse overall survival [HR 1.16, 95% CI (1.05, 1.28) p<0.002].
Figure: Kaplan-Meier survival analyses of patients with NSCLC treated with ICIs according to early steroid use
The use of ≥ 10 mg of prednisone equivalent corticosteroid dose within 30 days of initiating ICIs was associated with shorter time on treatment and worse overall survival in this large real world cohort of NSCLC patients. It is prudent that clinicians judiciously prescribe corticosteroids upon initiation of ICIs.